Laurus Labs Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 15,397,309 (49%) | — | ₹65,593 Cr |
| NII (HNI) | — | 4,619,194 (15%) | — | ₹19,678 Cr |
| Retail | — | 10,778,118 (35%) | — | ₹45,915 Cr |
| Σ Total | — | 31,116,785 (100%) | — | ₹1,325,575 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 35 | ₹14,910 |
| Retail (Max) | 13 | 455 | ₹193,830 |
| S-HNI (Min) | 14 | 490 | ₹208,740 |
| B-HNI (Min) | 67 | 2,345 | ₹998,970 |
Financial Statements (₹`in million)
| Metric | 31-Mar-16 | 31-Mar-15 | 31-Mar-14 |
|---|---|---|---|
| Revenue | 17,884 | 13,604 | 11,685 |
| Profit After Tax | 1,436 | 735 | 972 |
| Total Assets | 23,083 | 18,925 | 12,731 |
| Reserves & Surplus | 8,526 | 7,850 | 6,451 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Pre-payment of term loans – 226.29
- General corporate purposes – 60.42
Company Overview
About Laurus Labs Ltd.
Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.
Laurus Labs operates in four business lines:
1. Generics active pharmaceutical ingredients (APIs) - The development, manufacture and sale of APIs and advanced intermediates.
2. Generics finished dosage forms (FDFs) - The development and manufacture of oral solid formulations.
3. Synthesis - Contract development and manufacturing services for global pharmaceutical companies.
4. Ingredients - The manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors.
Key Highlights:
1. Laurus Labs launched 59 products since our inception in 2005.
2. Nine out of the 10 largest generic pharmaceutical companies in the world are its customers.
3. Laurus Labs employed 587 scientists at our R&D center in Hyderabad and 12 scientists at R&D centre in Greater Boston USA.
4. The Company owned 32 patents and had 150 pending patent applications, in several countries.
5. Company has three manufacturing facilities in Visakhapatnam, Andhra Pradesh.
6. Company sells its products in 32 countries in Sub-Saharan Africa, South-East Asia and Latin America.
Key Strengths:
1. Leadership in APIs in Select, High Growth Therapeutic Areas
2. Strong R&D Capabilities and Process Chemistry Skills
3. Industry Leading, Modern and Regulatory Compliant Manufacturing Capacities
4. Long-standing Relationships with Multi-National Pharmaceutical Companies
5. Experienced Promoters and Qualified Operational Personnel
6. Established Track Record of Delivering Growth